Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.01
+0.83%
HEALTHCARE · Cap: $6.01B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.26
+0.83%
HEALTHCARE · Cap: $58.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 148059% more annual revenue ($4.62T vs $3.12B). AMRX leads profitability with a 5.0% profit margin vs -3.5%. AMRX earns a higher WallStSmart Score of 56/100 (C).
AMRX
Buy56
out of 100
Grade: C
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.5%
Fair Value
$20.56
Current Price
$17.01
$3.55 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 157.1% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
Premium valuation, high expectations priced in
5.0% margin — thin
Trading at 170.1x book value
ROE of -881.0% — below average capital efficiency
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AMRX
The strongest argument for AMRX centers on EPS Growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.43 suggests the stock is reasonably priced for its growth.
Bear Case : AMRX
The primary concerns for AMRX are P/E Ratio, Profit Margin, Price/Book. Debt-to-equity of 84.54 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AMRX profiles as a value stock while TAK is a turnaround play — different risk/reward profiles.
AMRX carries more volatility with a beta of 1.24 — expect wider price swings.
TAK is growing revenue faster at 10.2% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Bottom Line
AMRX scores higher overall (56/100 vs 53/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amneal Pharmaceuticals, Inc. Class A Common Stock
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?